MX2017003216A - Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. - Google Patents

Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.

Info

Publication number
MX2017003216A
MX2017003216A MX2017003216A MX2017003216A MX2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A MX 2017003216 A MX2017003216 A MX 2017003216A
Authority
MX
Mexico
Prior art keywords
antagonists
progression
psoriatic arthritis
structural damage
inhibit
Prior art date
Application number
MX2017003216A
Other languages
English (en)
Inventor
Mpofu Shephard
Richards Hanno
LIGOZIO Gregory
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017003216A publication Critical patent/MX2017003216A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente descripción se refiere a métodos, usos, medicamentos, formulaciones farmacéuticas, formas de dosificación, y kits para la inhibición de la progresión del daño estructural en la artritis psoriásica (APS) de los pacientes el uso de IL-17 de los antagonistas, por ejemplo, anticuerpos IL-17 y fragmentos de unión a antígeno del mismo, por ejemplo, secukinumab.
MX2017003216A 2014-09-10 2015-09-08 Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. MX2017003216A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
MX2017003216A true MX2017003216A (es) 2017-05-23

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003216A MX2017003216A (es) 2014-09-10 2015-09-08 Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.

Country Status (11)

Country Link
US (2) US11278618B2 (es)
EP (1) EP3191120B1 (es)
JP (3) JP2017528465A (es)
KR (2) KR20230170796A (es)
CN (4) CN113069542A (es)
AU (2) AU2015313827C1 (es)
BR (1) BR112017003332A2 (es)
CA (1) CA2960754A1 (es)
MX (1) MX2017003216A (es)
RU (1) RU2697383C2 (es)
WO (1) WO2016038538A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
KR20180067676A (ko) 2015-10-27 2018-06-20 유씨비 바이오파마 에스피알엘 항-il-17a/f 항체를 사용한 치료 방법
US10676522B2 (en) * 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
JP7212675B2 (ja) * 2017-08-23 2023-01-25 イーライ リリー アンド カンパニー 性器乾癬の治療
JP2021501752A (ja) * 2017-11-02 2021-01-21 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用して腱障害を治療する方法
AU2020288749A1 (en) * 2019-06-04 2022-02-03 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
KR102604172B1 (ko) 2019-12-05 2023-11-22 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 베체트병 또는 류마티스 관절염 예방 또는 치료용 약학조성물
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL2481753T3 (pl) 2005-12-13 2018-09-28 Eli Lilly And Company Przeciwciała anty-IL-17
WO2007117749A2 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies fpr treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
EP4137514A1 (en) * 2010-10-08 2023-02-22 Novartis AG Methods of treating psoriasis using il-17 antagonists
KR20180129991A (ko) * 2010-11-05 2018-12-05 노파르티스 아게 Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
CA2856252A1 (en) 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
CA2960754A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Also Published As

Publication number Publication date
WO2016038538A1 (en) 2016-03-17
CN115944734A (zh) 2023-04-11
CN113069542A (zh) 2021-07-06
RU2697383C2 (ru) 2019-08-13
EP3191120B1 (en) 2024-04-10
US20170281762A1 (en) 2017-10-05
BR112017003332A2 (pt) 2017-11-28
JP7288927B2 (ja) 2023-06-08
CN107073110A (zh) 2017-08-18
CN115957326A (zh) 2023-04-14
RU2017107501A3 (es) 2019-03-12
KR20230170796A (ko) 2023-12-19
AU2018201410A1 (en) 2018-03-22
AU2015313827A1 (en) 2017-02-16
CA2960754A1 (en) 2016-03-17
AU2015313827C1 (en) 2018-08-30
EP3191120A1 (en) 2017-07-19
AU2015313827B2 (en) 2018-02-15
JP2023109973A (ja) 2023-08-08
JP2021152021A (ja) 2021-09-30
RU2017107501A (ru) 2018-10-10
KR20170045240A (ko) 2017-04-26
US11278618B2 (en) 2022-03-22
US20220313818A1 (en) 2022-10-06
JP2017528465A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
NZ737399A (en) Ccr2 modulators
AU2019268062A1 (en) Benzoquinolone inhibitors of VMAT2
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MY187540A (en) Compounds active towards bromodomains
PH12016500094A1 (en) Autotaxin inhibitors
EA201691582A1 (ru) Новые фармацевтические препараты
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
PH12014501991B1 (en) Phenicol antibacterials
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
TW201613864A (en) Novel compounds
MX2021010472A (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
AR100944A1 (es) ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
NZ727456A (en) Fused triterpene compounds and uses thereof
MX371343B (es) Moduladores del receptor x hepatico (lxr).